Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Inhaled MBS-COV in Healthy Participants
NCT05677893Phase 1Completed
- Sponsor
- Oneness Biotech Co., Ltd.
- Start
- Nov 2022
- Primary completion
- Mar 2023
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Investigational drug (MBS-COV) with Placebo (2 arms). Primary endpoint: Number of Participants With Treatment-emergent Adverse Events at 1 month. Started Nov 2022; status: completed.
02
Drugs
SNS812
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05677893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05677893.